Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus R-CHOP followed by ibrutinib maintenance in untreated ABC-DLBCL (IPI ≥2)
2024-511641-18-00Phase 2Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival (PFS). Planned start Dec 2024; status: authorised.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-511641-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511641-18-00.